These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
870 related items for PubMed ID: 30015301
1. Lipid management in ACS: Should we go lower faster? Gencer B, Mach F. Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301 [Abstract] [Full Text] [Related]
4. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*. Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446 [Abstract] [Full Text] [Related]
6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K, Sharma M, Ferdinand KC. Nutr Metab Cardiovasc Dis; 2016 Oct 19; 26(10):853-62. PubMed ID: 27352986 [Abstract] [Full Text] [Related]
7. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N, Tocci G, Ferri C. High Blood Press Cardiovasc Prev; 2018 Mar 19; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
9. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM. Circ Cardiovasc Qual Outcomes; 2018 May 19; 11(5):e004652. PubMed ID: 29748356 [Abstract] [Full Text] [Related]
10. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Atherosclerosis; 2018 Aug 19; 275():262-264. PubMed ID: 29980053 [Abstract] [Full Text] [Related]
11. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Atherosclerosis; 2019 Sep 19; 288():85-93. PubMed ID: 31349086 [Abstract] [Full Text] [Related]
15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia. Toth PP, Worthy G, Gandra SR, Sattar N, Bray S, Cheng LI, Bridges I, Worth GM, Dent R, Forbes CA, Deshpande S, Ross J, Kleijnen J, Stroes ESG. J Am Heart Assoc; 2017 Oct 02; 6(10):. PubMed ID: 28971955 [Abstract] [Full Text] [Related]
19. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM. Atherosclerosis; 2018 Sep 02; 276():124-130. PubMed ID: 30059843 [Abstract] [Full Text] [Related]